Empowered Patient Podcast

Scott Pescatore, Executive VP of the Rare Diseases Business at Recordati, is focused on rare and ultra-orphan diseases with high unmet needs by acquiring promising compounds from other companies and advancing them through development and approval. An example is the company's drug Isturisa, acquired from Novartis, which is an FDA-approved effective treatment for patients with Cushing syndrome, a rare endocrine condition. Raising awareness of rare diseases among physicians, patients, and the general public is a priority for Recordati to improve diagnosis rates and clinical trial participation, and to encourage more research and funding in the rare disease space. Scott explains, "We have two primary divisions at Recordati. One is our specialty primary care business, and the other is the rare disease business, which I have the honor and privilege to look after. And we have a very simple sort of work ethic or business mantra, if you will, and that's focused on the few. And we really dedicate ourselves to focusing on disease areas and patient groups and therapeutic areas that have a high unmet need and really low or limited options for patients. And really focusing on diseases and areas that are rare and considered ultra-orphan by the definitions in the US, where really there's a very small patient base. And that's where we began back in 2007, when the rare disease business was formed. And that's really what our focus has been since then. And we continue to focus on this segment of the market." "So Isturisa is really a fantastic product. We acquired this product through a deal we did with Novartis Pharmaceuticals back in 2019, and this product has FDA approval for patients who have endogenous hypercortisolemia with Cushing syndrome. So it's quite a nasty disease, but it's a very efficacious product. The product is what's considered a cortisol inhibitor in the blocks in a particular enzyme to help normalize hypercortisolemia in patients with Cushing syndrome. And Cushing syndrome, for those who aren't familiar, is a rare endocrine condition that really has a significant impact on patients' quality of life, on the caregivers, on the families. And the indication I mentioned was supported by quite robust phase 3 trials." #Recordati #RareDisease #FocusedontheFew #CushingSyndrome #IMCD #CastlemansDisease recordati.com Download the transcript here

Martin Burns, CEO of Bruin Biometrics, is focused on preventing pressure injuries, which are often not detected through visual and tactile assessments because damage starts invisibly under the skin. The Bruin scanner technology identifies pressure injuries by measuring sub-epidermal moisture, which can predict later tissue death, highlighting the condition that can be treated before it develops further. This handheld device is skin tone agnostic, addressing a significant health disparity and providing an objective number indicating the presence of excess fluid, allowing clinicians to act quickly. Martin explains, "They are surprisingly common, and I emphasize surprisingly because pressure injuries are typically not talked about in the mainstream, but actually they affect about three to three and a half million patients a year in the US. And really shockingly, of those three to three and a half million, about 60,000 people die from them every year. So think about that as in the list of the top 10 leading causes of mortality in the United States, which is the surprising part. When you speak to friends and relatives, they've often heard of them potentially as bedsores, but nobody really has an appreciation of just how significant they are. How widespread or how deadly." "The initial stages of it are imperceptible to any practitioner, but are actually measurable by objective technologies, and they don't become visibly manifest or physically manifest until much later. And what happens is they end up breaking the skin surface. As you can imagine, every time the skin is broken is an opening for infections and significant complications, which actually is the thing that ends up causing huge amounts of additional lengths of stay and costly treatments. And to the extent that those don't work, mortality." "Thankfully, our scanner is one in which the mechanism it uses disregards skin tone entirely. In other words, skin color doesn't matter for the scanner. What we are measuring is an increase or a decrease in fluid at the specific site that we're measuring. And so it's skin tone agnostic, which is rather brilliant because dark skin tone patients die at a rate four times more than any other cohort, which is an absolute travesty and one in which it simply doesn't need to happen. And our scanner is a leading reason why it doesn't need to happen." #BruinBiometrics #Prevention #PressureInjuries #HospitalSafety #PressureInjuryPrevention #PatientSafety #Hospitals bruinbiometrics.com Download the transcript here

Robert Jacks, President and CEO of Sparrow Pharmaceuticals, identifies that an elevated cortisol level is a newly recognized cause of treatment-resistant type 2 diabetes. A significant portion of patients with diabetes who do not respond to standard treatments, including GLP-1 agonists, have underlying high cortisol. Sparrow has developed a drug designed to lower cortisol levels inside cells, directly addressing the underlying driver of the disease, and to be used as a complement to existing treatments. This concept of targeting cortisol-driven resistance could be extended to other conditions, such as treatment-resistant hypertension. Robert explains, "I feel as though Sparrow has come full circle, actually, with the mechanism of our drug. Originally, we have a drug that targets HSD-1. We can talk about what that is, but it's involved in intracellular cortisol regulation. This was a class of drugs that was originally developed targeting cardiometabolic diseases like type 2 diabetes. And the drugs had some moderate efficacy, but they weren't well differentiated in a broad population and largely were just continued for commercial reasons." "Our company was founded a number of years ago based on the idea that these drugs had real potential but hadn't been used in the right patient population. And that being the patient population with the disease that we know is driven by excess cortisol toxicity, because that's aligned with the mechanism, as I was mentioning. So we generated some really interesting data in a rare disease called Endogenous Cushing syndrome. This is a very severe orphan disease with patients who have very severely elevated cortisol, showing in fact that yes, this mechanism does seem like it could have a very major impact in the right patient population." "Simultaneously, another company published some data showing that actually there's a very large population of people with treatment-resistant type 2 diabetes, a very high level of medical need, and that their underlying disease actually is being driven by elevated levels of cortisol. And so when you bring together the data that we generated and what appears to be a large amount needed in a large population, it seems like we may have the perfect solution for that. So we've refocused our efforts on a broad population of treatment-resistant type 2 diabetes in patients whose disease is being impacted or driven by elevated cortisol levels." #SparrowPharmaceuticals #Type2Diabetes #CardiometabolicDisease #CortisolRegulation #Cortisol #GLP1 #RareDisease sparrowpharma.com Download the transcript here

Jesse Levey, CEO and Founder of Longevity Health, has a focus on extending the health span not just the lifespan of more people by providing access to tools and preventative health information. Lessons learned from expensive concierge medical services are being applied to a broader population, driving down health costs and democratizing longevity medicine. Using AI to build a scalable and personalized approach to wellness not just sick care, Longevity Health aims to make an AI doctor available around the globe. Jesse explains, "Our mission is to help a billion people live to a hundred in good health. That's the vision. And the way that we get there is by building an AI doctor trains of ed on longevity medicine and distributed around the world. We have a three-phased business model. Phase one is to take the sort of hundred-thousand-dollar-a-year longevity concierge experience and deliver it for $10,000. So we've taken this really high-end experience that combines an executive physical with a longevity concierge physician and a team to help you implement the recommendations. And we've delivered that for $10,000. That's been around for about two years." "Phase two takes that down to $1,000 with the help of AI. So it reduces the time spent by humans and the need to spend a lot of time with clinicians. And so it's a mix between clinician time and AI interactions. And then eventually, as the regulation allows and as the technology improves, we believe that we'll be able to deliver this experience for as low as $10 a month or $100 a year via an AI doctor. And so that's the future. That's what we're building towards." #LongevityHealth #Longevity #HealthyAging #HealthSpan #FunctionalMedicine #HealthAI #Aging longevityhealth.me Download the transcript here

Sean Cassidy, CEO and Co-Founder of Lucem Health, is applying AI to identify patients at high risk of undiagnosed conditions like cancer and diabetes. The goal is to facilitate earlier diagnosis and treatment by flagging patients that need screening based on the AI plaform's ability to analyze EHR data and demographics of diverse patient populations to ensure broad scalability. This technology was designed to integrate into existing clinical workflows for established screening procedures rather than making direct treatment recommendations. Sean explains, "The origin of the company, the idea for the company, originated within Mayo Clinic in about 2020. Mayo Clinic has faced a challenge, and I think sometimes continues to face a challenge that a lot of researchers in AI have faced, which is how do you get promising AI in a clinical context from the so-called bench to the bedside? How do you get it from the lab into clinical practice? And what they realized was that while the data science and the AI part of it is really interesting, what was needed was scaffolding around the AI to facilitate integration with data and integration with workflows, a measurement and monitoring system, and so on and so forth." "We are trying to facilitate, and you're going to see us begin to expand the aperture, if you like, or open the aperture of how we position the company. Because as we've gone on, we have realized that the opportunity here is to actually help healthcare provider organizations, health systems, and so on, create really high-impact care delivery programs that have at their core or feature at their core earlier diagnosis, accelerated treatment, earlier treatment and therefore better outcomes for patients and hopefully even saved lives. So that's the generic approach that we take." #LucemHealth #AIinHealthcare #HealthcareAI #HealthTech #EarlyDiseaseDetection lucemhealth.com Download the transcript here

Dr. Waqaas Al-Siddiq, CEO and Founder of Biotricity, has designed a direct-to-consumer service to shift healthcare from a reactive to a preventive model by simplifying and accelerating access to remote cardiac screening. Applying AI to sift through patient data allows the cardiologist to focus on clinically relevant information and to identify sporadic, intermittent heart issues that are often difficult to detect using traditional heart screening techniques. Waqaas predicts an expansion of specialized solutions using AI and large datasets to support clinicians and patients in the drive to identify early signs of disease. Waqaas explains, "The thing that we've been focused on is, as you know, heart issues. We've talked extensively about heart issues, which are the number one killer. And so what we've done now is we've collected this massive dataset, but we're trying to look at the nuances of those needles in a haystack. So it's not about the individuals who have arrhythmias to catch. It's about the ones who are very, very sporadic and intermittent, something that happens once every four months. Is there a way to predict that? Can we grab additional data from the patient about their environment, about their history, to get a more holistic view of the patient? " "Often, with a massive amount of data in a set, you can get into prediction, but you need a more holistic view. Our focus has now been on now that we've captured 90% of the scenarios, the last 10% are incredibly complicated, and how do we leverage that? How do we use our data to basically get into those specialized nuances?" #HeartSecure #hearthealth #preventative #heartdiease #healthyheart #selfcare #healthylifestyle #healthtestathome #HeartYourHeart #Biotricity #CareInnovation #HealthcareAI #Bioheart #Cardiology biotricity.com Download the transcript here

Neil Klompas, President and CEO of Augurex, has a mission to improve the diagnosis of autoimmune diseases, with a primary focus on axial spondyloarthritis, a form of inflammatory back pain that is often misdiagnosed. The Augurex blood test SpineStat is designed to differentiate axSpA from mechanical back pain by identifying a specific biomarker present in axSpA. Currently, there is an average nine-year delay from the onset of symptoms to an accurate diagnosis of axSpA, causing irreversible spinal damage and years of using drugs and therapy with no benefit. Neil explains, "I think we're all familiar with back pain. Some of the NIH data and WHO data out there show that almost 28% of adult Americans live with chronic back pain, back pain lasting more than three months. It can be a real journey to figure out what the drivers are, with some patients really never getting resolution, resulting in pain management and, in some cases, even opioid pain management. But if you dive deeper into that category of back pain, there are really two broad classifications we can think about. We can think about mechanical back pain, which is due to lifting, twisting, sports injury, or maybe a car accident. But then there's this whole other category, as you indicated, called inflammatory back pain, which really has its roots in autoimmune, where the body's immune system is actually attacking itself. " "Well, this is when the body's immune system attacks its peripheral joints. In inflammatory back pain, or as you said, axial spondyloarthritis, it's an autoimmune condition where the body's immune system actually attacks the spine. This can lead to pain increasing over time, new bone growth, fusion of the spinal cord, and permanent stiffness and loss of mobility. It's progressive. It keeps getting worse, and because it's an autoimmune condition. Simply stretching or swearing to take up yoga or getting a new pair of runners or doing PT or massage, while it might help with some of the symptoms, it's not going to slow down or stop the disease. The challenge with axSpA, with axial spondyloarthritis, is that while it's not really that well known or talked about in the media, it's actually more than twice as prevalent as rheumatoid arthritis, a condition which many people have heard about." #Augurex #AdvancedDiagnostics #AutoimmuneDiseases #axSpA #AxialSpondyloarthritis #BackPain augurex.com Download the transcript here

Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, describes the development of bexmarilimad, a novel first-in-class immunotherapy that, unlike existing checkpoint inhibitors targeting T cells, targets the Clever 1 receptor on macrophages. This treatment is designed to reprogram the tumor microenvironment by switching marcophages from suppressive to active, enabling the patient's immune system to recognize and attack cancer cells. The primary disease target is higher-risk Myelodysplastic syndromes because the cancer cells in virtually all MDS patients express the Clever 1 target. Petri explains, "We are developing a completely new type of treatment. Currently, cancer patients are treated with immunotherapies called checkpoint inhibitors that target immune checkpoints. But our approach is targeting completely different cells, not T cells, but rather macrophages. And that's why we are first in class with a novel mode of action. And that's why it's important that these macrophages are shown to, for example, contribute to treatment resistance in many tumors." "Clever 1 actually is a receptor that was identified about 20 years ago. It found a certain macrophage as well as myeloid cells. And Clever 1 keeps the immune system in a tolerant and suppressive state. In cancer, for example, these Clever 1-positive macrophages essentially help the malignancy grow instead of helping to fight against it. And then our approach is that we want to block Clever 1 with our monoclonal antibody, bexmarilimab. So those macrophages switch the phenotype into an active antigen, preventing a pro-inflammatory state, and this reawakens immune surveillance. It allows T cells in the system to actually recognize the malignant cells themselves as dangerous and mount a proper antitumor response. So, a completely new mode of action by targeting Clever 1, we are not just adding another cytotoxic mechanism. We are removing the immune break and enabling the patient's own immune system to do the job that it was originally designed to do." #FaronPharmaceuticals #BloodCancer #MDS #MyelodysplasticSyndrome #HR-MDS #CancerResearch #novelimmunotherapy #Bexmarilimab #Clever1 faron.com Download the transcript here

Todd Doze, CEO of Janus Health, specializes in bringing AI to hospitals to connect the hospital revenue cycle management with the overall patient experience. Automating some manual RCM tasks, such as prior authorizations and referrals, has led to significant reductions in claim denials, faster processing times, fewer errors, and better compliance with recent legislation. Challenges remain to ensure the AI model's accuracy and to demonstrate clear ROI and a direct impact on the hospital's revenue. Todd explains, "Today at Janus, we focus on helping providers improve their operational and financial efficiency. We work with about 250 acute care hospitals across the country, servicing some of the largest health systems in the nation by providing automations and AI-driven operational intelligence. This gives management insight into what their revenue cycle folks are doing to ensure they're taking the optimal paths to adjudicate claims and also automating as much of the laborious, tedious work that goes into treating patients in the most optimal manner." "There are a lot of very manual pain points within the rev cycle experience. For example, many of us have been referred by our primary care physician to a specialty provider. A very common example is referring to an imaging center for an MRI or X-ray. And many times, to access an appointment with that specialty provider, the provider may need to submit a prior authorization request to the patient's insurance. And then there's also the communication loop process focused on the referral. And so there are many areas for error, and there are a lot of ways the patient experience can go south very quickly." #JanusHealth #AIinHealthcare #HealthcareAI #HealthTech #HealthcareOperations #RCM janus-ai.com Download the transcript here

Susan Grant, Chief Clinical Officer at symplr, reviews findings from their annual Compass Survey, which revealed the significant challenges hospitals face, driven by financial pressures, clinician burnout, and operational inefficiencies. Fragmented technology systems create significant administrative burdens, and there is growing recognition that unifying healthcare operations and strategically implementing AI are crucial to streamlining workflows. Clinicians' involvement in the design and implementation of new processes and procedures is essential to ensure that patients' real-world needs are properly addressed. Susan explains, "The annual Compass Survey, is actually our fourth survey that we've done here at symplr, and the goal of the survey is to drive awareness around the need for and benefits of streamlining healthcare operations software. So it's a way to get feedback from our customers, clients, and leaders out in the healthcare world." "I've been a Chief Nurse for the last 30 years in different health systems around the country, and we do tend to be a very reactive industry. However, I think it's built and intensified over the last few years because of issues we're seeing that have also intensified, including finances, workplace violence, clinician burnout, and cybersecurity. Those are some of the top issues our healthcare systems are dealing with. So I think that the reactivity of trying to really deal with those various issues has intensified and created this reactivity." #symplr #CompassSurvey #HealthcareIT #HealthcareOperations #symplrOperationsPlatform #HealthcareAI symplr.com Download the transcript here

Fawad Butt, Co-Founder and CEO of Penguin AI, is addressing the workflow challenges faced by healthcare payers and providers, particularly in prior authorizations and claims adjudications. These processes are inefficient and often yield inconsistent results because human reviewers interpret rules differently, and patients are denied care due to minor administrative errors. Penguin AI is bringing consistency and speed to adjudication, breaking down data silos and handling non-clinical administrative work, enabling agents to address patient-specific problems and ensure accuracy and safety. Fawad explains, "When you look at the healthcare ecosystem, there are obviously the pharma side, the payer side, the provider side, and the PBN side. So there are lots of areas where opportunities exist. We think payers and providers are especially challenged, and I think the area where they struggle is in the administrative workflow. And these are things like prior authorization and risk adjustment, claims adjudication, and payment integrity on the payer side." "There are things like scheduling and patient 360, or onboarding and referrals, as well as some risk adjustment for entities that are risk-bearing, and ultimately, all the functions around revenue cycle management for providers. I think the payers and providers have a tremendous amount of technology and resourcing support, but these functions have not really been what I would say reimagined in over a decade. And I think with AI, there is a real opportunity to come back and try to optimize." #PenguinAI #HealthAI #HealthcareAdministration penguinai.co Download the transcript here

Alexander Tsiaras, CEO and Founder of StoryMD, is addressing the critical problem of the fragmented health information landscape. The StoryMD platform unifies a patient's health history, including clinical records, wearable data, and personal diary entries, along with relevant data from a vast validated medical library of text and strong visualizations. This provides a coherent narrative about the patient that informs the patient, their healthcare providers, and caregivers, enabling more informed decisions and better outcomes. Alexander explains, "So one of the huge problems that we have in healthcare is that when people go through a health journey, they have to cobble information together from so many disparate sources. You get a PDF here, you get a URL there, you get a screenshot somewhere else. And fundamentally, what happens is that you're trying to cobble the story of your journey together, and it's totally fragmented. You get fragmented medical records, you get fragmented information, and you share fragmented information with other sources. So really the story is constantly evolving, and you're trying to figure it out, and it's problematic." "What we have now built is the largest coded medical library in the world, where we can take all of the information using HL7 codes. Now, HL7 is Health Level Seven International, which basically is the way that your medical records are coded. And we have mapped a piece of information using AI to your medical records. So when we see a lab report, we tell you a beautiful story about what your labs mean, and this way, we can actually keep longitudinal stories going, giving you insights into what's going on in your biomarkers." #StoryMD #HealthTech #DigitalHealth #HealthAI #HealthJourney storymd.com Download the transcript here

Seth Cohen, President of Cedar, is addressing the affordability of health care by shifting the emphasis from billing functionality to patient financial navigation by using technology to connect patients to underutilized financial resources. The Cedar Cover platform is designed to identify and enroll eligible uninsured or underinsured patients into Medicaid, ACA, available pharmaceutical copay subsidies, and untapped Health Savings Accounts, which can be used retrospectively to cover previous medical and ongoing bills, benefiting the patient and providers. An AI agent handles patient service calls to help patients navigate the challenges of connecting to these resources and identifying new coverage options in these uncertain times. Seth explains, "Cedar is the largest independent solution focused entirely on the patient financial experience in healthcare. As you probably know, in the revenue cycle space, there are lots of vendors out there selling solutions up and down the revenue cycle, mostly with an emphasis on insurance reimbursement. We are the only one that we're aware of that is really driving at scale a better patient experience, so fully focused there. And so what that means is we are the entity responsible for sending bills to patients and helping those patients navigate their financial obligations to large hospitals, health systems, and large physician groups." "But that word advocacy, I think, is very relevant now because what we've discovered and a huge, huge shift over the last decade is that most patients cannot afford the bills they're receiving. We're really in an affordability crisis. And so it's less about sending a bill with good billing functionality. It's more about helping the patient navigate how to manage that bill. And so there is a lot of advocacy in that." #Cedar #FinancialSupport #MedicalBills cedar.com Download the transcript here

Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations. Jim explains, "Fundamentally speaking, if we look at everybody on this planet from a DNA and RNA perspective, there are 8 billion people, and each one of us is different from the others due to our DNA and RNA. So if we acknowledge that biologically we're all different, then the problem that we're trying to solve is if we're all different, why are we treating each patient with the same standard of care? A process that has existed for a hundred years, and again, they've made substantial advancements, but functional precision medicine is really an opportunity to move away from a standard that's based on the laws of averages and really treat people based on an individual level, developed by results that come from their individual biology." "In oncology, these practices and standards have been developed over decades. And in some situations, some of these cancer protocols haven't been updated in decades. There had been continual advancements in things like immunotherapy. What I'll say is that in oncology, they're always looking for the silver bullet. It's in the genome, it's in a biomarker, it's in immuno-oncology, it's in an organoid, it's in all of those types of things. So they have always tried to find that silver bullet. Fundamentally, what we do in First Ascent is that we believe that we have enough bullets, per se. We have enough drugs, per se. We're just not using them in the right ways. " #FirstAscentBiomedical #Cancer #Oncology firstascentbiomedical.com Download the transcript here

Deb Nevins, Director of Product Strategy at POCN, emphasizes the expanding role and importance of Nurse Practitioners and Physician Associates in the American healthcare system. These professionals have evolved from being an extension of the physician to becoming autonomous clinicians who handle a wide range of patient care, including diagnosing, prescribing, and creating treatment plans for a significant portion of the patient population. In many cases, NPs and PAs are filling care gaps in rural and underserved areas and applying a more holistic approach to healthcare in an increasingly virtual healthcare environment. Deb explains, "POCN is an organization that has been around for over 10 years now. It started really with the mission to support nurse practitioners and physician associates and help them practice at the top of their license. And we do that multiple ways, but specifically we like to say it's a learn, earn, care, and connect model. So we provide educational insights to them. We allow them to connect with each other on our platforms, and we also bring them forward to pharmaceutical companies to help them better understand the role that they play in patient care today." "Well, it's really interesting because both nurse practitioners and physician associates have really stepped up their responsibilities and roles since the timeframe when COVID started, where there was such a backlog. So they used to be thought of as more physician extenders or as mid-levels, but we can no longer say that. So nurse practitioners, physicians, and associates will handle everything with patient care from the initial intake, counseling, diagnosing, creating the treatment plan, prescribing medications, doing the follow-up, and ensuring that they're managing during side effects or anything like that that might happen. They support the patient with access challenges as they try to get their medications. So they basically do almost everything that a physician, an MD or a DO would do, except that they're not doing surgery or they're not doing super complex cases, but they have autonomy." #ElevatingCare #VoicesInCare #PatientsFirstCare #POCN #WomenInHealthcare #VisibilityMatters #HealthcareLeadership #AmplifyNPs #AmplifyPAs pocn.com Download the transcript here

Jill Eubank, Division President of Professional Talent Solutions at Randstad USA, shares key findings from the Randstad Work Monitor Pulse Survey on the current landscape in the medical and healthcare industry. Noted is the significant shift from prioritizing remote work to job security, alignment with leadership values, and how AI is being used to improve job efficiency. In an environment facing a scarcity of qualified employees, retention drivers include pay increases that keep pace with inflation, flexible scheduling, and strong manager support. Jill explains, "We're the largest staffing and workforce solution provider in the country and really in the world. We offer recruiting, staffing, HR services, whether it's on a temporary contingent basis or even all the way up to executive search and permanent placement. In healthcare specifically, our co consultants specialize in recruiting for those essential roles in the healthcare industry. Think medical, dental, and pharmaceutical sectors. We have a large, extensive network of not only clients in healthcare, but also candidates and a pool of talent in the market." "I think during COVID, we saw, especially in the healthcare industry, people wanting to find a way to work remotely for a lot of various reasons. What you're finding is that it's now shifting to employability versus working remotely. And in order to stay in a role for, let's say, five years or more, what we're finding is healthcare workers are saying that the top three retention drivers are an annual pay increase that keeps up with inflation or above inflation, followed by manager support, which was something we hadn't seen as frequently in the healthcare space. And then obviously, something that has evolved over the last couple of years is alignment with leadership values. A lot of very interesting key takeaways, but things you're starting to see evolve with the market and what's happening just with the workforce in general." #RandstadUSA #TalentStrategy #WorkforceInsights #FutureofWork #HealthcareJobs #TalenRetention #WorkplaceTrends #HealthcareLeadership #EmployeeWellbeing #FutureofWork randstadusa.com Download the transcript here

David Bates, CEO and Co-Founder of Linus Health, highlights the need to monitor brain health to identify the earliest signs of cognitive decline. The Linus Health AI-powered platform enables primary care providers to quickly screen for, diagnose, and help manage cognitive issues for an expanding population. Striving to overcome stigma and bias, this approach to early detection is crucial because many underlying causes of cognitive decline are treatable or reversible. David explains, "In brain health, especially, I'll talk first about cognitive health. There are up to 15 million Americans right now who have mild cognitive impairment, which is a precursor to dementia, and they do not know it. So, it's believed that up to 92% of mild cognitive impairment is undiagnosed, and up to 60% of dementia is undiagnosed. So we have this massive need to identify these folks and help them, empower them to get the resources to manage the condition, to optimize quality of life for themselves and their family and their loved ones. On the preventative side, empower folks to prevent dementia as much as possible, and maybe even half of dementia cases could be prevented through lifestyle modification." "Furthermore, if it's found early, there's a lot that can be done both to prepare for the advancement of the disease and to delay the advancement of the disease, and to empower people to live the highest quality of life in their circumstances. Furthermore, not all mild cognitive impairment or dementia is due to Alzheimer's disease. There are some things that, especially in the mild cognitive impairment stage, can be done, like changing medications, diagnosing depression, dealing with sleep apnea, vitamin deficiencies, and so on and so forth, that can actually reverse the course or at least slow the progression." #LinusHealth #BrainHealth #AI #Healthcare #EarlyDetection #CognitiveHealth #HealthTech #Innovation linushealth.com Download the transcript here

Mike Hoxter, CTO of Lightbeam Health Solutions, is focused on applying AI to population health management by using predictive models to enhance risk stratification for organizations with value-based care contracts. He emphasizes the importance of integrating social determinants of health along with clinical data to create more accurate predictive scores for patient outcomes, such as reducing hospital readmissions. AI enables a model to incorporate diverse data to derive more fine-tuned, actionable predictions. Mike explains, "We're really all for optimization in value-based care plans and care management. That's really our bread and butter, which is a pretty wide net. So we have a lot of large provider organizations in either CMS MSSP, ACO REACH, or a wide range of value-based care contracts with a lot of the commercial players. The Blues, Humana, Cigna, and Aetna all have value-based care plans that they have contracts with providers. So, optimizing for performance in those contracts. Anybody who works within those is our main clientele. We also have payers that are administering value-based care plans and some hospital systems as well." "If you're good at preventative healthcare, you prevent a lot of unnecessary healthcare. And so risk stratification is something that we do a lot of, and we use a lot of the standard models out there. We have Johns Hopkins embedded into our application. We have all of the different HCC models for Medicare Advantage, CDPs for Medicaid, but then also we have a suite of internal machine-learning-based models, which, I think, is funny - we've gotten to a point where there's such a thing as traditional AI, which is what it's called." #LightbeamHealthSolutions #PopulationHealth #ValueBasedCare #VBC #VBCEnablement #AI #SDOH #RemotePatientMonitoring #Providers #Payers #ACO lightbeamhealth.com Download the transcript here

Adam David, CEO of Doctors House Calls, has identified a gap in healthcare for homebound, high-acuity patients who lack a primary care physician, which often leads to frequent hospital admissions. This service operates primarily for Medicare patients by deploying physicians, PAs, and nurse practitioners to provide comprehensive care in patients' homes. Technology, such as connected devices, AI, and portable diagnostic equipment, enables efficient and effective visits to provide proactive care, extending the range of services available to this population. Adam explains, "I put together Doctors House Calls, not to compete in the business of treating patients in assisted living facilities, which seems to be very popular among independent physicians looking to be more mobile and not wanting to work within four walls." "And so they see facility-based type of care as a way to sort of get out and be mobile and have flexibility, but they're only servicing patients that are in facilities. I would say there are probably more patients who need this type of help who are still living in independent homes than who are actually in facilities. A lot of it's due to their socioeconomic needs. They just don't have the support around them to help guide them. They don't have social services that are in place to tell them what their options are. And so they're sort of just left at home by themselves." "What I've done is over the course of about eight years, I've been working on building a group of nurse practitioners, physician associates, and physicians who are really willing to drive way out of their way at times and drive many miles just to see one patient to make sure that they're receiving the care they need." #DoctorsHouseCalls #HomeHealthcare #MobileMedicine #AccessibleCare #CareContinuity doctorshousecalls.com Download the transcript here

Linda Schatz, Director of AKASA, explains the role of Clinical Documentation Integrity (CDI) specialists in ensuring accurate coding and bridging the gap between clinical documentation and specific, accurate codes to ensure proper reimbursement. The complexity of medical coding often leads to errors, which can be nearly eliminated by using AI to review 100% of patient encounters to identify inconsistencies and help CDI and coding professionals process more accurate claims quickly. Accurate documentation is important for hospital revenue, patient care quality, and perception of the hospital's performance. Linda explains, "Well, the old adage, if it isn't documented, it wasn't done. If the doctor uses incorrect or perfectly acceptable medical terminology, it doesn't translate into an appropriate code. You've heard the term UIs, this is years ago, right? Grandma had UTIs and died. In the coding world, that used to code for a simple UTI. So the hospitals are getting paid for a patient that took care of a UTI, when in reality that patient was septic. To the outside world, it looks like Grandma came to the hospital, something that could have been treated outpatient, and she died. So the public perception of quality is less. So not only is it revenue, it's quality, but ultimately it's delivering patient care." "I'm an old nurse. I've been in this field for over 40 years. I've worked across the NICU, PICU, and adult ICU. I've worked in access hospitals to large academics and all the way through hospice. That's pretty unique as a nurse to have that big of a background. Then I became a CDS, or clinical documentation specialist, or integrity specialist, and learned the documentation and coding aspect." "Then I moved into the consulting role and worked with organizations and physicians all across this nation, helping them learn how to do this. And so you've got the clinical background, the coding background, and now I understand how generative AI works. And so while you're a new nurse, you're a horse, right? When we hear a heartbeat, we think of a horse, and after years, you earn your stripes and you become a zebra, and then you add all of these multiple areas of expertise, you become uniquely valuable as a pink zebra." #AKASA #GenAI #CDI #RevenueCycleManagement akasa.com Download the transcript here